Related Experiment Video

Updated: Jul 13, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer

Cheryl Ho1, Angela Davies, Philip Mack

  • 1University of California, Davis Cancer Center, Sacramento, CA, USA. cho@bccancer.bc.ca

Clinical Lung Cancer
|August 8, 2007
PubMed

Insights

Dual inhibition of the epidermal growth factor receptor (EGFR) pathway may overcome resistance in advanced non-small-cell lung cancer. Clinical trials are evaluating combined EGFR inhibition strategies for improved efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) pathway is a key target in advanced non-small-cell lung cancer (NSCLC).
  • Current therapies involve inhibiting EGFR tyrosine kinase or receptor binding, but face limitations like resistance and incomplete efficacy.
  • Alternative cellular mechanisms can drive proliferation despite single-target inhibition.

Purpose of the Study:

  • To explore the potential of dual inhibition of the EGFR pathway to overcome therapeutic limitations in advanced NSCLC.
  • To investigate whether combining EGFR inhibition strategies can improve treatment efficacy.
  • To review preclinical data and ongoing clinical trials for combined EGFR inhibition.

Main Methods:

  • Review of preclinical data on dual EGFR inhibition strategies.
  • Analysis of mechanisms underlying resistance to single-agent EGFR inhibitors.
  • Examination of ongoing clinical trials assessing combined EGFR inhibition in NSCLC.

Main Results:

  • Preclinical studies suggest dual EGFR inhibition may overcome resistance and enhance anti-cancer effects.
  • Combined inhibition theoretically addresses multiple resistance pathways simultaneously.
  • Clinical trials are actively investigating the safety and efficacy of these dual approaches.

Conclusions:

  • Dual inhibition of the EGFR pathway presents a promising strategy for advanced NSCLC.
  • Overcoming resistance through combined EGFR blockade may improve patient outcomes.
  • Further clinical investigation is warranted to establish the role of dual EGFR inhibition in NSCLC treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...